Therapeutic inertia and contributing factors among ambulatory patients with hypertension.

BMC Cardiovasc Disord

Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Ethiopia, Mekelle, Tigray.

Published: September 2024

AI Article Synopsis

  • Therapeutic inertia is the reluctance of healthcare providers to escalate treatment for patients with poorly controlled hypertension, even when guidelines suggest otherwise, and it has become a key reason for inadequate hypertension management.
  • This study aimed to explore the prevalence and causes of therapeutic inertia specifically among ambulatory patients with hypertension at a cardiac clinic in northern Ethiopia, involving 282 participants tracked over six months.
  • The findings revealed that 72% of participants with uncontrolled hypertension experienced therapeutic inertia, leading to recommendations for increased medication dose or the introduction of additional drugs to improve treatment outcomes.

Article Abstract

Background: Therapeutic inertia refers to the failure of healthcare providers to initiate or intensify therapy based on current evidence-based guidelines, even when the desired treatment goal is not achieved. Despite poorly controlled hypertension, clinicians often hesitate to intensify treatment. Therapeutic inertia is currently receiving more attention as a significant reason for clinicians' inability to effectively manage hypertension. However, in our setting, there is limited knowledge about therapeutic inertia and its contributing factors.

Objectives: The aim of this study was to investigate therapeutic inertia and contributing factors among ambulatory patients with hypertension.

Method: A prospective observational study was conducted at the cardiac clinic of Ayder comprehensive specialized hospital in the Tigray region of northern Ethiopia. Patients were recruited into the study during their medication refilling appointments using a simple random sampling technique. All patients were followed for a minimum of 6 months to assess therapeutic inertia, which was defined as the healthcare providers' failure to initiate or intensify therapy based on current evidence-based guidelines when therapeutic goals were not achieved. Data were collected through patient interviews and review of their medical records. We utilized binary logistic regression analysis to determine factors associated with therapeutic inertia.

Result: The study included 282 participants, with an equal male-to-female ratio. The mean age of the participants was 56.6 ± 12.3 years. Among all participants, a majority (67.4%) had uncontrolled hypertension. The study revealed that 72% of patients with uncontrolled hypertension experienced therapeutic inertia. In response to this issue, we recommended dose escalation for 73% of the patients and the initiation of additional drug therapy for 27% of them. Multivariable analysis indicated that having three or more medications (AOR = 4.74, 95%CI = 1.94-11.61) and having stage II hypertension (AOR = 3.06, 95%CI = 1.32-7.08) were identified as independent predictors of therapeutic inertia.

Conclusion: The findings of our study indicated that a large proportion of the patients had poorly controlled hypertension, and a significant number of these patients also demonstrated therapeutic inertia. The number of medications and stage II hypertension were identified as independent predictors of therapeutic inertia. Therefore, it is crucial to prioritize patients at risk of therapeutic inertia and provide them with additional support. Moreover, practice based training should be given to clinicians in order to enhance treatment intensification and overall treatment outcome among ambulatory patients with hypertension.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429490PMC
http://dx.doi.org/10.1186/s12872-024-04109-1DOI Listing

Publication Analysis

Top Keywords

therapeutic inertia
40
therapeutic
13
inertia contributing
12
ambulatory patients
12
patients
10
hypertension
9
inertia
9
contributing factors
8
factors ambulatory
8
patients hypertension
8

Similar Publications

Introduction: Tackling the inertia of growing threat of antimicrobial resistance (AMR) requires changes in how antibiotics are prescribed and utilized. The monitoring of antimicrobial prescribing in hospitals is a critical component in optimizing antibiotic use. Point prevalence surveys (PPSs) enable the surveillance of antibiotic prescribing at the patient level in small hospitals that lack the resources to establish antimicrobial stewardship programs (ASP).

View Article and Find Full Text PDF

Importance: Despite guideline recommendations to use low-molecular-weight heparins (LMWHs) or direct oral anticoagulants in the treatment of most patients with acute pulmonary embolism (PE), US-based studies have found increasing use of unfractionated heparin (UFH) in hospitalized patients.

Objective: To identify barriers and facilitators of guideline-concordant anticoagulation in patients hospitalized with acute PE.

Design, Setting, And Participants: This qualitative study conducted semistructured interviews from February 1 to June 3, 2024, that were recorded, transcribed, and analyzed in an iterative process using reflexive thematic analysis.

View Article and Find Full Text PDF

Background: Clinical inertia is common when blood pressure (BP) is high in the office. Little is known about the extent of clinical inertia after ambulatory BP monitoring (ABPM).

Methods: This was an electronic health record-based retrospective cohort study of patients with high office BP (≥140/90 mmHg) referred for ABPM at a medical center in New York City between 2016 and 2020.

View Article and Find Full Text PDF

Aims: To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co-formulation of basal, and bolus insulin, in a real-world setting.

Materials And Methods: A 20-week, prospective, single-arm, open-label, non-interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti-hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon-like peptide-1 receptor agonists. The primary endpoint was a change in HbA from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!